Orakl Oncology Raises $34M Series A to Expand AI Cancer Drug Prediction

Orakl Oncology secured $34M in a Series A round led by Norrsken VC and Singular to expand its AI-driven cancer drug prediction platform. The company will broaden its dataset, grow its AI team, and extend research beyond colorectal and pancreatic cancers to lung and gastric cancers, aiming to enhance drug program predictions and target discovery.